Pelvital research shows efficacy of non-invasive treatment for stress urinary incontinence
Significant benefits and efficacy of transvaginal mechanotherapy
For millions of women, stress urinary incontinence (SUI) – the involuntary leakage of urine during activities like coughing, laughing, or exercising – is a frustrating and often embarrassing condition. Surgery has long been considered the most effective treatment, but new research suggests a non-invasive alternative could be just as effective.
The women’s health MedTech company Pelvital has announced that a review paper published in the peer-reviewed journal Continence Reports has found that ‘transvaginal mechanotherapy’, a treatment that uses a small device to stimulate and strengthen pelvic floor muscles, could serve as a first-line therapy for SUI.
The approach works by using gentle mechanical pressure to activate and train weakened muscles, improving bladder control over time.
The study followed women using this therapy and found that women who used transvaginal mechanotherapy experienced significant improvements in both pad weight reduction and quality of life.
Additionally, outcomes were superior to pelvic floor muscle training, with some achieving results comparable to those seen with surgery. Unlike traditional pelvic floor exercises (Kegels), which require discipline and proper technique, transvaginal mechanotherapy provides consistent, targeted stimulation, making it easier for patients to see results.
"I am proud to be a part of this crucial article that highlights the evidence behind transvaginal mechanotherapy as a groundbreaking advancement for the millions of women struggling with stress urinary incontinence," says Leah Fulker, DPT and Pelvital Patient Support Manager.
"There is a significant gap in care for women with urinary incontinence, leaving many without access to effective treatment options. By prescribing this first-line conservative treatment that is used in the home, Family Medicine and OB/Gyn physicians can bridge this gap, providing women with a safe, effective, and accessible solution that delivers lasting results and significantly improves quality of life."
What sets this treatment apart is its accessibility. Unlike surgery, which comes with risks and recovery time, transvaginal mechanotherapy can be done at home with a simple, guided program. Experts believe this could be a game-changer for the millions of women hesitant to undergo surgery or those who have struggled with pelvic floor exercises in the past.
Pelvital’s first product is Flyte, an FDA-cleared novel in-home treatment for stress urinary incontinence and weakened pelvic floor muscles. Flyte is the first and only in-home product to deliver the therapeutic treatment modality of mechanotherapy to the pelvic floor.
"Pelvital is committed to advancing the science of women's health and expanding access to effective, evidence-based treatments," says Lydia Zeller, CEO of Pelvital.
"This paper validates the effectiveness of transvaginal mechanotherapy as a first-line treatment and reinforces our mission to provide clinicians and women with a proven, accessible, non-invasive solution."